Role of Tau Protein in Neuronal Damage in Alzheimer's Disease and Down Syndrome

Archives of Medical Research

Volumn 43, Issue 8, 2012, Pages 645-654

  Cárdenas, Ana M ^a   Ardiles, Alvaro O ^a   Barraza, Natalia ^a   Baéz Matus, Ximena ^a   Caviedes, Pablo ^b  

^a UNIVERSIDAD DE VALPARAÍSO   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

Author keywords

Alzheimer's disease; Amyloid precursor protein; Down syndrome; Dyrk1A; Rcan; Tau protein

Indexed keywords

AMYLOID PRECURSOR PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; AUTOSOME; CELL LINE; CYTOSKELETON; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOWN SYNDROME; GENE EXPRESSION; HUMAN; NERVE CELL LESION; NERVE FIBER TRANSPORT; NONHUMAN; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; TRISOMY 21;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; DOWN SYNDROME; HUMANS; NERVE DEGENERATION; NEURODEGENERATIVE DISEASES; NEURONS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; TAU PROTEINS;

EID: 84871662000     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2012.10.012     Document Type: Review

References (163)

1. Goedert M., Spillantini M.G., Jakes R., et al. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 1989, 3:519-526.
2. Mavilia C., Couchie D., Nunez J. Diversity of high-molecular-weight tau proteins in different regions of the nervous system. J Neurochem 1994, 63:2300-2306.
3. Kosik K.S., Orecchio L.D., Bakalis S., et al. Developmentally regulated expression of specific tau sequences. Neuron 1989, 2:1389-1397.
4. Goedert M., Jakes R. Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization. EMBO J 1990, 9:4225-4230.
5. Panda D., Samuel J.C., Massie M., et al. Differential regulation of microtubule dynamics by three- and four-repeat tau: implications for the onset of neurodegenerative disease. Proc Natl Acad Sci USA 2003, 100:9548-9553.
6. Goode B.L., Feinstein S.C. Identification of a novel microtubule binding and assembly domain in the developmentally regulated inter-repeat region of tau. J Cell Biol 1994, 124:769-782.
7. Lee G., Neve R.L., Kosik K.S. The microtubule binding domain of tau protein. Neuron 1989, 2:1615-1624.
8. Shi J., Zhang T., Zhou C., et al. Increased dosage of Dyrk1A alters alternative splicing factor (ASF)-regulated alternative splicing of tau in Down syndrome. J Biol Chem 2008, 283:28660-28669.
9. Ingram E.M., Spillantini M.G. Tau gene mutations: dissecting the pathogenesis of FTDP-17. Trends Mol Med 2002, 8:555-562.
10. van Swieten J.C., Bronner I.F., Azmani A., et al. The DeltaK280 mutation in MAP tau favors exon 10 skipping in vivo. J Neuropathol Exp Neurol 2007, 66:17-25.
11. Bronner I.F., ter Meulen B.C., Azmani A., et al. Hereditary Pick's disease with the G272V tau mutation shows predominant three-repeat tau pathology. Brain 2005, 128:2645-2653.
12. Chambers C.B., Lee J.M., Troncoso J.C., et al. Overexpression of four-repeat tau mRNA isoforms in progressive supranuclear palsy but not in Alzheimer's disease. Ann Neurol 1999, 46:325-332.
13. Ingelsson M., Ramasamy K., Russ C., et al. Increase in the relative expression of tau with four microtubule binding repeat regions in frontotemporal lobar degeneration and progressive supranuclear palsy brains. Acta Neuropathol 2007, 114:471-479.
14. Smith P.Y., Delay C., Girard J., et al. MicroRNA-132 loss is associated with tau exon 10 inclusion in progressive supranuclear palsy. Hum Mol Genet 2011, 20:4016-4024.
15. Arai T., Ikeda K., Akiyama H., et al. Distinct isoforms of tau aggregated in neurons and glial cells in brains of patients with Pick's disease, corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol 2001, 101:167-173.
16. Lindwall G., Cole R.D. Phosphorylation affects the ability of tau protein to promote microtubule assembly. J Biol Chem 1984, 259:5301-5305.
17. Biernat J., Gustke N., Drewes G., et al. Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. Neuron 1993, 11:153-163.
18. Bramblett G.T., Goedert M., Jakes R., et al. Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron 1993, 10:1089-1099.
19. Wagner U., Utton M., Gallo J.M., et al. Cellular phosphorylation of tau by GSK-3 beta influences tau binding to microtubules and microtubule organisation. J Cell Sci 1996, 109:1537-1543.
20. Schneider A., Biernat J., von Bergen M., et al. Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry 1999, 38:3549-3558.
21. Takahashi S., Saito T., Hisanaga S., et al. Tau phosphorylation by cyclin-dependent kinase 5/p39 during brain development reduces its affinity for microtubules. J Biol Chem 2003, 278:10506-10515.
22. Hanger D.P., Anderton B.H., Noble W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med 2009, 15:112-119.
23. Lee G. Tau and src family tyrosine kinases. Biochim Biophys Acta 2005, 1739:323-330.
24. Reynolds C.H., Betts J.C., Blackstock W.P., et al. Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3beta. J Neurochem 2000, 74:1587-1595.
25. Stoothoff W.H., Johnson G.V. Tau phosphorylation: physiological and pathological consequences. Biochim Biophys Acta 2005, 1739:280-297.
26. Billingsley M.L., Kincaid R.L. Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. Biochem J 1997, 323:577-591.
27. Alonso A.C., Zaidi T., Grundke-Iqbal I., et al. Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci USA 1994, 91:5562-5566.
28. Alonso A.C., Grundke-Iqbal I., Iqbal K. Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med 1996, 2:783-787.
29. Alonso A., Zaidi T., Novak M., et al. Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci USA 2001, 98:6923-6928.
30. Engel T., Hernandez F., Avila J., et al. Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J Neurosci 2006, 26:5083-5090.
31. Plattner F., Angelo M., Giese K.P. The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J Biol Chem 2006, 281:25457-25465.
32. Rankin C.A., Sun Q., Gamblin T.C. Tau phosphorylation by GSK-3beta promotes tangle-like filament morphology. Mol Neurodegener 2007, 2:12.
33. Pei J.J., Grundke-Iqbal I., Iqbal K., et al. Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration. Brain Res 1998, 797:267-277.
34. Cruz J.C., Tseng H.C., Goldman J.A., et al. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 2003, 40:471-483.
35. Li T., Hawkes C., Qureshi H.Y., et al. Cyclin-dependent protein kinase 5 primes microtubule-associated protein tau site-specifically for glycogen synthase kinase 3beta. Biochemistry 2006, 45:3134-3145.
36. Lee S., Hall G.F., Shea T.B. Potentiation of tau aggregation by cdk5 and GSK3β. J Alzheimers Dis 2011, 26:355-364.
37. Derkinderen P., Scales T.M., Hanger D.P., et al. Tyrosine 394 is phosphorylated in Alzheimer's paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase. J Neurosci 2005, 25:6584-6593.
38. Salminen A., Kaarniranta K., Haapasalo A., et al. AMP-activated protein kinase. A potential player in Alzheimer's disease. J Neurochem 2011, 118:460-474.
39. Tremblay M.A., Acker C.M., Davies P. Tau phosphorylated at tyrosine 394 is found in Alzheimer's disease tangles and can be a product of the Abl-related kinase. Arg. J Alzheimers Dis 2010, 19:721-733.
40. Vingtdeux V., Chandakkar P., Zhao H., et al. Novel synthetic small-molecule activators of AMPK as enhancers of autophagy and amyloid-beta peptide degradation. FASEB J 2011, 25:219-231.
41. Ferrer I., Barrachina M., Puig B., et al. Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models. Neurobiol Dis 2005, 20:392-400.
42. Liu F., Liang Z., Wegiel J., et al. Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome. FASEB J 2008, 22:3224-3233.
43. Ryoo S.R., Jeong H.K., Radnaabazar C., et al. DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer disease. J Biol Chem 2007, 282:34850-34857.
44. Wegiel J., Dowjat K., Kaczmarski W., et al. The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome. Acta Neuropathol 2008, 116:391-407.
45. Wegiel J., Kaczmarski W., Barua M., et al. Link between DYRK1A overexpression and several-fold enhancement of neurofibrillary degeneration with 3-repeat tau protein in Down syndrome. J Neuropathol Exp Neurol 2011, 70:36-50.
46. Delacourte A., Défossez A. Biochemical characterization of an immune serum which specifically marks neurons in neurofibrillary degeneration in Alzheimer's disease. CR Acad Sci III 1986, 303:439-444.
47. Grundke-Iqbal I., Iqbal K., Tung Y.C., et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 1986, 83:4913-4917.
48. Kosik K.S., Joachim C.L., Selkoe D.J. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci USA 1986, 83:4044-4048.
49. Nukina N., Ihara Y. One of the antigenic determinants of paired helical filaments is related to tau protein. J Biochem 1986, 99:1541-1544.
50. Wood J.G., Mirra S.S., Pollock N.J., et al. Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau (tau). Proc Natl Acad Sci USA 1986, 83:4040-4043.
51. Ihara Y., Nukina N., Miura R., et al. Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer's disease. J Biochem 1986, 99:1807-1810.
52. Iqbal K., Grundke-Iqbal I., Zaidi T., et al. Defective brain microtubule assembly in Alzheimer's disease. Lancet 1986, 2:421-426.
53. Joachim C.L., Morris J.H., Kosik K.S., et al. Tau antisera recognize neurofibrillary tangles in a range of neurodegenerative disorders. Ann Neurol 1987, 22:514-520.
54. Shankar S.K., Yanagihara R., Garruto R.M., et al. Immunocytochemical characterization of neurofibrillary tangles in amyotrophic lateral sclerosis and parkinsonism-dementia of Guam. Ann Neurol 1989, 25:146-151.
55. Love S., Bridges L.R., Case C.P. Neurofibrillary tangles in Niemann-Pick disease type C. Brain 1995, 118:119-129.
56. Boeve B.F., Hutton M. Refining frontotemporal dementia with parkinsonism linked to chromosome 17: introducing FTDP-17 (MAPT) and FTDP-17 (PGRN). Arch Neurol 2008, 65:460-464.
57. Goedert M., Jakes R. Mutations causing neurodegenerative tauopathies. Biochim Biophys Acta 2005, 1739:240-250.
58. Hong M., Zhukareva V., Vogelsberg-Ragaglia V., et al. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 1998, 282:1914-1917.
59. Pérez M., Lim F., Arrasate M., et al. The FTDP-17-linked mutation R406W abolishes the interaction of phosphorylated tau with microtubules. J Neurochem 2000, 4:2583-2589.
60. Hasegawa M., Smith M.J., Goedert M. Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly. FEBS Lett 1998, 437:207-210.
61. Bunker J.M., Kamath K., Wilson L., et al. FTDP-17 mutations compromise the ability of tau to regulate microtubule dynamics in cells. J Biol Chem 2006, 281:11856-11863.
62. LeBoeuf A.C., Levy S.F., Gaylord M., et al. FTDP-17 mutations in Tau alter the regulation of microtubule dynamics: an alternative core model for normal and pathological Tau action. J Biol Chem 2008, 283:36406-36415.
63. Han D., Qureshi H.Y., Lu Y., et al. Familial FTDP-17 missense mutations inhibit microtubule assembly-promoting activity of tau by increasing phosphorylation at Ser202 in vitro. J Biol Chem 2009, 284:13422-13433.
64. Crowther R.A., Goedert M. Abnormal tau-containing filaments in neurodegenerative diseases. J Struct Biol 2000, 130:271-279.
65. Lin W.L., Lewis J., Yen S.H., et al. Filamentous tau in oligodendrocytes and astrocytes of transgenic mice expressing the human tau isoform with the P301L mutation. Am J Pathol 2003, 162:213-218.
66. Taniguchi T., Doe N., Matsuyama S., et al. Transgenic mice expressing mutant (N279K) human tau show mutation dependent cognitive deficits without neurofibrillary tangle formation. FEBS Lett 2005, 579:5704-5712.
67. Dawson H.N., Cantillana V., Chen L., et al. The tau N279K exon 10 splicing mutation recapitulates frontotemporal dementia and parkinsonism linked to chromosome 17 tauopathy in a mouse model. J Neurosci 2007, 27:9155-9168.
68. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001, 81:741-766.
69. Arriagada P.V., Growdon J.H., Hedley-Whyte E.T., et al. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992, 42:631-639.
70. Holzer M., Holzapfel H.P., Zedlick D., et al. Abnormally phosphorylated tau protein in Alzheimer's disease: heterogeneity of individual regional distribution and relationship to clinical severity. Neuroscience 1994, 63:499-516.
71. Dickson D.W., Crystal H.A., Bevona C., et al. Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging 1995, 16:285-298.
72. Oddo S., Caccamo A., Kitazawa M., et al. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging 2003, 24:1063-1070.
73. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
74. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
75. Burdick D., Soreghan B., Kwon M., et al. Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs. J Biol Chem 1992, 267:546-554.
76. Jarrett J.T., Berger E.P., Lansbury P.T. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993, 32:4693-4697.
77. Bitan G., Kirkitadze M.D., Lomakin A., et al. Amyloid beta-protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc Natl Acad Sci USA 2003, 100:330-335.
78. Jacobsen J.S., Wu C.C., Redwine J.M., et al. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2006, 103:5161-5166.
79. Lesne S., Koh M.T., Kotilinek L., et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440:352-357.
80. Selkoe D.J. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 2008, 192:106-113.
81. Shankar G.M., Li S., Mehta T.H., et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008, 14:837-842.
82. Ardiles A.O., Tapia-Rojas C.C., Mandal M., et al. Postsynaptic dysfunction is associated with spatial and object recognition memory loss in a natural model of Alzheimer's disease. Proc Natl Acad Sci USA 2012, 109:13835-13840.
83. Lauren J., Gimbel D.A., Nygaard H.B., et al. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 2009, 457:1128-1132.
84. Zhao W.Q., Santini F., Breese R., et al. Inhibition of calcineurin-mediated endocytosis and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors prevents amyloid beta oligomer-induced synaptic disruption. J Biol Chem 2010, 285:7619-7632.
85. Lacor P.N., Buniel M.C., Furlow P.W., et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 2007, 27:796-807.
86. Renner M., Lacor P.N., Velasco P.T., et al. Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron 2010, 66:739-754.
87. Mucke L., Selkoe D.J. Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med 2012, 2:a006338.
88. Lewis J., Dickson D.W., Lin W.L., et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001, 293:1487-1491.
89. Ribe E.M., Perez M., Puig B., et al. Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice. Neurobiol Dis 2005, 20:814-822.
90. Vogelsberg-Ragaglia V., Schuck T., Trojanowski J.Q., et al. PP2A mRNA expression is quantitatively decreased in Alzheimer's disease hippocampus. Exp Neurol 2001, 168:402-412.
91. Otth C., Concha I.I., Arendt T., et al. AbetaPP induces cdk5-dependent tau hyperphosphorylation in transgenic mice Tg2576. J Alzheimers Dis 2002, 4:417-430.
92. Hoshi M., Sato M., Matsumoto S., et al. Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta. Proc Natl Acad Sci USA 2003, 100:6370-6375.
93. Zheng W.H., Bastianetto S., Mennicken F., et al. Amyloid beta peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures. Neuroscience 2002, 115:201-211.
94. Ma Q.L., Yang F., Rosario E.R., et al. Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J Neurosci 2009, 29:9078-9089.
95. Gotz J., Chen F., van Dorpe J., et al. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 2001, 293:1491-1495.
96. Roberson E.D., Halabisky B., Yoo J.W., et al. Amyloid-beta/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J Neurosci 2011, 31:700-711.
97. Rank K.B., Pauley A.M., Bhattacharya K., et al. Direct interaction of soluble human recombinant tau protein with Abeta 1-42 results in tau aggregation and hyperphosphorylation by tau protein kinase II. FEBS Lett 2002, 514:263-268.
98. Oddo S., Vasilevko V., Caccamo A., et al. Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem 2006, 281:39413-39423.
99. Roberson E.D., Scearce-Levie K., Palop J.J., et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007, 316:750-754.
100. Morris R.G., Moser E.I., Riedel G., et al. Elements of a neurobiological theory of the hippocampus: the role of activity-dependent synaptic plasticity in memory. Philos Trans R Soc Lond B Biol Sci 2003, 358:773-786.
101. Shipton O.A., Leitz J.R., Dworzak J., et al. Tau protein is required for amyloid {beta}-induced impairment of hippocampal long-term potentiation. J Neurosci 2011, 31:1688-1692.
102. Polydoro M., Acker C.M., Dukk K., et al. Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J Neurosci 2009, 29:10741-10749.
103. Papasozomenos S.C., Binder L.I. Phosphorylation determines two distinct species of Tau in the central nervous system. Cell Motil Cytoskeleton 1987, 8:210-226.
104. Hoover B.R., Reed M.N., Su J., et al. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 2010, 68:1067-1081.
105. Mandelkow E.M., Stamer K., Vogel R., et al. Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol Aging 2003, 24:1079-1085.
106. Ittner L.M., Ke Y.D., Delerue F., et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 2010, 142:387-397.
107. Bittner T., Fuhrmann M., Burgold S., et al. Multiple events lead to dendritic spine loss in triple transgenic Alzheimer's disease mice. PLoS ONE 2010, 5:e15477.
108. + elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J Neurosci 2010, 30:11938-11950.
109. De Vos K.J., Grierson A.J., Ackerley S., et al. Role of axonal transport in neurodegenerative diseases. Annu Rev Neurosci 2008, 31:151-173.
110. Pigino G., Morfini G., Atagi Y., et al. Disruption of fast axonal transport is a pathogenic mechanism for intraneuronal amyloid beta. Proc Natl Acad Sci USA 2009, 106:5907-5912.
111. Bilsland L.G., Sahai E., Kelly G., et al. Deficits in axonal transport precede ALS symptoms in vivo. Proc Natl Acad Sci USA 2010, 107:20523-20528.
112. Maccioni R.B., Cambiazo V. Role of microtubule-associated proteins in the control of microtubule assembly. Physiol Rev 1995, 75:835-864.
113. Busciglio J., Lorenzo A., Yeh J., et al. Beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 1995, 14:879-888.
114. Alonso A.D., Grundke-Iqbal I., Barra H.S., et al. Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. Proc Natl Acad Sci USA 1997, 94:298-303.
115. King M.E., Kan H.M., Baas P.W., et al. Tau-dependent microtubule disassembly initiated by prefibrillar beta-amyloid. J Cell Biol 2006, 175:541-546.
116. Decker H., Lo K.Y., Unger S.M., et al. Amyloid-beta peptide oligomers disrupt axonal transport through an NMDA receptor-dependent mechanism that is mediated by glycogen synthase kinase 3beta in primary cultured hippocampal neurons. J Neurosci 2010, 30:9166-9171.
117. Mattson M.P., Cheng B., Davis D., et al. Beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 1992, 12:376-389.
118. Rapoport M., Dawson H.N., Binder L.I., et al. Tau is essential to beta-amyloid-induced neurotoxicity. Proc Natl Acad Sci USA 2002, 99:6364-6369.
119. Tackenberg C., Brandt R. Divergent pathways mediate spine alterations and cell death induced by amyloid-beta, wild-type tau, and R406W tau. J Neurosci 2009, 29:14439-14450.
120. Vossel K.A., Zhang K., Brodbeck J., et al. Tau reduction prevents Abeta-induced defects in axonal transport. Science 2010, 330:198.
121. Wang J.Z., Grundke-Iqbal I., Iqbal K. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci 2007, 25:59-68.
122. Karran E., Mercken M., De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 2011, 10:698-712.
123. Epstein C.J. Developmental genetics. Experientia 1986, 42:1117-1128.
124. Epstein C.J., Weil J., Epstein L.B. Abnormalities in the interferon response and immune systems in Down syndrome: studies in human trisomy 21 and mouse trisomy 16. Prog Clin Biol Res 1987, 246:191-208.
125. Head E., Silverman W., Patterson D., et al. Aging and Down Syndrome. Curr Gerontol Geriatr Res 2012, 2012:412536.
126. Pulsifer M.B. The neuropsychology of mental retardation. J Int Neuropsychol Soc 1996, 2:159-176.
127. Hattori M., Fujiyama A., Taylor T.D., et al. Chromosome 21 mapping and sequencing consortium. The DNA sequence of human chromosome 21. Nature 2000, 405:311-319.
128. Reeves R.H., Gearhart J.D., Littlefield J.W. Genetic basis for a mouse model of Down syndrome. Brain Res Bull 1986, 16:803-814.
129. Ault B., Caviedes P., Rapoport S.I. Neurophysiological abnormalities in cultured dorsal root ganglion neurons from the trisomy-16 mouse fetus, a model for Down syndrome. Brain Res 1989, 485:165-170.
130. Galceran J., de Graaf K., Tejedor F.J., et al. The MNB/DYRK1A protein kinase: genetic and biochemical properties. J Neural Transm Suppl 2003, 67:139-148.
131. Woods Y.L., Cohen P., Becker W., et al. The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase. Biochem J 2001, 355:609-615.
132. Kimura R., Kamino K., Yamamoto M., et al. The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease. Hum Mol Genet 2007, 16:15-23.
133. Qian W., Liang H., Shi J., et al. Regulation of the alternative splicing of tau exon 10 by SC35 and Dyrk1A. Nucleic Acids Res 2011, 39:6161-6171.
134. Yin X., Jin N., Gu J., et al. Dual-specificity-tyrosine-phosphorylated and regulated kinase 1A (Dyrk1A) modulates serine-arginine rich protein 55 (SRp55)-promoted tau exon 10 inclusion. J Biol Chem 2012, 287:30497-30506.
135. Wiese A.G., Pacifici R.E., Davies K.J. Transient adaptation of oxidative stress in mammalian cells. Arch Biochem Biophys 1995, 318:231-240.
136. Crawford D.R., Leahy K.P., Abramova N., et al. Hamster adapt78 mRNA is a Down syndrome critical region homologue that is inducible by oxidative stress. Arch Biochem Biophys 1997, 342:6-12.
137. Fuentes J.J., Pritchard M.A., Planas A.M., et al. A new human gene from the Down syndrome critical region encodes a proline-rich protein highly expressed in fetal brain and heart. Hum Mol Genet 1995, 4:1935-1944.
138. Fuentes J.J., Genescà L., Kingsbury T.J., et al. DSCR1, overexpressed in Down syndrome, is an inhibitor of calcineurin-mediated signaling pathways. Hum Mol Genet 2000, 9:1681-1690.
139. Ermak G., Morgan T.E., Davies K.J. Chronic overexpression of the calcineurin inhibitory gene DSCR1 (Adapt78) is associated with Alzheimer's disease. J Biol Chem 2001, 276:38787-38794.
140. Cook C.N., Hejna M.J., Magnuson D.J., et al. Expression of calcipressin1, an inhibitor of the phosphatase calcineurin, is altered with aging and Alzheimer's disease. J Alzheimers Dis 2005, 8:63-73.
141. Harris C.D., Ermak G., Davies K.J. RCAN1-1L is overexpressed in neurons of Alzheimer's disease patients. FEBS J 2007, 274:1715-1724.
142. Ladner C.J., Czech J., Maurice J., et al. Reduction of calcineurin enzymatic activity in Alzheimer's disease: correlation with neuropathologic changes. J Neuropathol Exp Neurol 1996, 55:924-931.
143. Kayyali U.S., Zhang W., Yee A.G., et al. Cytoskeletal changes in the brains of mice lacking calcineurin A alpha. J Neurochem 1997, 68:1668-1678.
144. Ermak G., Harris C.D., Battocchio D., et al. RCAN1 (DSCR1 or Adapt78) stimulates expression of GSK-3beta. FEBS J 2006, 273:2100-2109.
145. Wagner U., Utton M., Gallo J.M., et al. Cellular phosphorylation of tau by GSK-3 beta influences tau binding to microtubules and microtubule organisation. J Cell Sci 1996, 109:1537-1543.
146. Holtzman D.M., Bayney R.M., Li Y.W., et al. Dysregulation of gene expression in mouse trisomy 16, an animal model of Down syndrome. EMBO J 1992, 11:619-627.
147. Cataldo A.M., Petanceska S., Peterhoff C.M., et al. App gene dosage modulates endosomal abnormalities of Alzheimer's disease in a segmental trisomy 16 mouse model of Down syndrome. J Neurosci 2003, 23:6788-6792.
148. Eckert A., Schulz K.L., Rhein V., et al. Convergence of amyloid-beta and tau pathologies on mitochondria in vivo. Mol Neurobiol 2010, 41:107-114.
149. Nathalie P., Jean-Noël O. Processing of amyloid precursor protein and amyloid peptide neurotoxicity. Curr Alzheimer Res 2008, 5:92-99.
150. Selenica M.L., Brownlow M., Jimenez J.P., et al. Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy. Neurodegener Dis 2012, Jul 10. [Epub ahead of print].
151. Ryoo S.R., Cho H.J., Lee H.W., et al. Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer's disease. J Neurochem 2008, 104:1333-1344.
152. Lee M.S., Kao S.C., Lemere C.A., et al. APP processing is regulated by cytoplasmic phosphorylation. J Cell Biol 2003, 163:83-95.
153. Judge M., Hornbeck L., Potter H., et al. Mitosis-specific phosphorylation of amyloid precursor protein at threonine 668 leads to its altered processing and association with centrosomes. Mol Neurodegener 2011, 6:80.
154. Lloret A., Badia M.C., Giraldo E., et al. Amyloid-β toxicity and tau hyperphosphorylation are linked via RCAN1 in Alzheimer's disease. J Alzheimers Dis 2011, 27:701-709.
155. Cárdenas A.M., Rodríguez M.P., Cortés M.P., et al. Calcium signals in cell lines derived from the cerebral cortex of normal and trisomy 16 mice. Neuroreport 1999, 10:363-369.
156. Saud K., Arriagada C., Cárdenas A.M., et al. Neuronal dysfunction in Down syndrome: contribution of neuronal models in cell culture. J Physiol Paris 2006, 99:201-210.
157. Opazo P., Saud K., de Saint Pierre M., et al. Knockdown of amyloid precursor protein normalizes cholinergic function in a cell line derived from the cerebral cortex of a trisomy 16 mouse: an animal model of down syndrome. J Neurosci Res 2006, 84:1303-1310.
158. Rojas G., Cárdenas A.M., Fernández-Olivares P., et al. Effect of the knockdown of amyloid precursor protein on intracellular calcium increases in a neuronal cell line derived from the cerebral cortex of a trisomy 16 mouse. Exp Neurol 2008, 209:234-242.
159. Acuña M., Noriega J., Perez-Nuñez R., et al. RCAN1 overexpression results in enhanced voltage-gated calcium currents via impairment of inactivation in a neuronal cell line derived from cerebral cortex of Ts16 mice, an animal model of Down Syndrome. Soc Neurosci Abstr 2011, 152.14.
160. Noriega J., Acuña M., Perez-Nuñez R., et al. Knockdown of Rcan1 and Dyrk1A ameliorate the cholinergic dysfunction in cell lines derived from the cerebral cortex of a Ts16 mouse, a model of Down syndrome: possible role of VaChT and CHT1 proteins as targets. Soc Neurosci Abstr 2011, 152.15.
161. Engelborghs S., Le Bastard N. The impact of cerebrospinal fluid biomarkers on the diagnosis of Alzheimer's disease. Mol Diagn Ther 2012, 16:135-141.
162. Vanderstichele H., Bibl M., Engelborghs S., et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement 2012, 8:65-73.
163. Wang D., Wang F., Tan Y., et al. Discovery of potent small molecule inhibitors of DYRK1A by structure-based virtual screening and bioassay. Bioorg Med Chem Lett 2012, 22:168-171.